Thermo Fisher Scientific Inc. (TMO) To Go Ex-Dividend on December 15th

Thermo Fisher Scientific Inc. (NYSE:TMO) announced a quarterly dividend on Thursday, November 5th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.47 per share by the medical research company on Friday, January 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th.

Thermo Fisher Scientific has raised its dividend payment by an average of 0.1% per year over the last three years and has increased its dividend annually for the last 8 consecutive years. Thermo Fisher Scientific has a dividend payout ratio of 7.6% meaning its dividend is sufficiently covered by earnings. Research analysts expect Thermo Fisher Scientific to earn $27.83 per share next year, which means the company should continue to be able to cover its $1.88 annual dividend with an expected future payout ratio of 6.8%.

Thermo Fisher Scientific Price Performance

TMO stock opened at $694.93 on Friday. The firm has a market cap of $257.48 billion, a price-to-earnings ratio of 27.61, a PEG ratio of 2.78 and a beta of 0.84. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The company’s fifty day simple moving average is $661.03 and its 200 day simple moving average is $554.78. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $712.17.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the previous year, the firm posted $5.79 EPS. The firm’s revenue was up 9.1% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific will post 25.26 earnings per share for the current year.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing the prior authorization, which had $1 billion remaining. The program has no expiration date and could support per-share results and signal confidence in the business. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
• Positive Sentiment: Recent quarterly results were better than expected: EPS of $6.68 beat the $6.40 consensus, while revenue of $12.14 billion exceeded estimates and increased 9.1% year over year. Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
• Positive Sentiment: Thermo Fisher declared a quarterly dividend of $0.47 per share, payable January 15, 2027. The annualized dividend is $1.88 per share, though the indicated yield is modest at about 0.3%. Thermo Fisher Scientific Announces Quarterly Dividend
• Positive Sentiment: The company introduced value-priced AmpSure qPCR master mixes, adding an offering aimed at labs seeking dependable testing performance at lower cost. Thermo Fisher Introduces AmpSure Universal qPCR Master Mixes
• Neutral Sentiment: Market research reports point to growth in oligonucleotide synthesis, mRNA manufacturing, protein labeling and Q-TOF mass spectrometry—areas related to Thermo Fisher’s markets. These industry forecasts suggest potential demand tailwinds, but do not provide company-specific sales or earnings guidance. Global Oligonucleotide Synthesis Services Market Report 2026

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research.

The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.